Inventor · disambiguated record
Cameron Smith
Also filed as: SMITH CAMERON · SMITH CAMERON J · SMITH CAMERON JAMES
52 granted patents·4 pending applications·480 citations·filing 2004–2024
98Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC24MERCK SHARP & DOHME13HUSFELD CRAIG4ALI AMJAD3SMITH CAMERON3
Top patents by PatentIndex Score
56 records- 0198US10526330B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 7, 2020·15 cites·13 claims
- 0298US10208040B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 19, 2019·24 cites·31 claims
- 0398US10196393B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 5, 2019·24 cites·12 claims
- 0498US10100049B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Oct 16, 2018·28 cites·17 claims
- 0597US10550118B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 4, 2020·13 cites·10 claims
- 0697US10519153B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 31, 2019·16 cites·22 claims
- 0797US10392386B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·19 cites·10 claims
- 0897US8449890B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2012·Granted May 28, 2013·68 cites·26 claims
- 0996US11634419B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 25, 2023·6 cites·20 claims
- 1096US8563512B2Neprilysin inhibitorsSMITH CAMERON·Filed 2011·Granted Oct 22, 2013·62 cites·22 claims
- 1195US10947229B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·10 cites·15 claims
- 1295US10836763B25 to 7 membered heterocyclic amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 17, 2020·12 cites·20 claims
- 1395US7652049B2CETP inhibitorsMERCK & CO INC·Filed 2005·Granted Jan 26, 2010·54 cites·54 claims
- 1494US11453668B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Sep 27, 2022·2 cites·20 claims
- 1594US8846913B2Neprilysin inhibitorsTHERAVANCE INC·Filed 2013·Granted Sep 30, 2014·18 cites·10 claims
- 1694US7915271B21,3-oxazolidin-2-one derivatives useful as CETP inhibitorsMERCK SHARP & DOHME·Filed 2006·Granted Mar 29, 2011·15 cites·21 claims
- 1793US11299492B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 12, 2022·2 cites·13 claims
- 1893US11254669B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 22, 2022·3 cites·17 claims
- 1992US10954237B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 23, 2021·2 cites·18 claims
- 2092US7910592B2CETP inhibitorsMERCK SHARP & DOHME·Filed 2006·Granted Mar 22, 2011·13 cites·15 claims
- 2189US7781426B2CETP inhibitorsMERCK SHARP & DOHME·Filed 2006·Granted Aug 24, 2010·18 cites·12 claims
- 2287US9365574B2Soluble guanylate cyclase activatorsRAGHAVAN SUBHAREKHA·Filed 2011·Granted Jun 14, 2016·22 cites·17 claims
- 2386US12398135B2Dimethyl amino azetidine amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2024·Granted Aug 26, 2025·0 cites·6 claims
- 2484US11878977B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jan 23, 2024·0 cites·5 claims
- 2584US8354454B2Prodrugs of oxazolidinone CETP inhibitorsMERCK SHARP & DOHME·Filed 2009·Granted Jan 15, 2013·7 cites·17 claims
- 2683US8334290B2CETP inhibitorsALI AMJAD·Filed 2006·Granted Dec 18, 2012·5 cites·12 claims
- 2782US8735435B2CETP inhibitorsALI AMJAD·Filed 2009·Granted May 27, 2014·5 cites·9 claims
- 2881US11667637B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jun 6, 2023·0 cites·19 claims
- 2980US10030027B2Soluble guanylate cyclase stimulatorsMERCK SHARP & DOHME·Filed 2016·Granted Jul 24, 2018·3 cites·56 claims
- 3080US9221834B2Cyclic amine substituted oxazolidinone CETP inhibitorLU ZHIJIAN·Filed 2011·Granted Dec 29, 2015·3 cites·14 claims
- 3179US11718616B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Aug 8, 2023·0 cites·7 claims
- 3279US9555041B2Neprilysin inhibitorsSMITH CAMERON·Filed 2015·Granted Jan 31, 2017·2 cites·17 claims
- 3379US9120758B2Neprilysin inhibitorsSMITH CAMERON·Filed 2013·Granted Sep 1, 2015·3 cites·34 claims
- 3479US2023322774A1Dimethyl amino azetidine amides as jak inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Application pending·0 cites
- 3577US8202891B2Quaternary ammonium compounds useful as muscarinic receptor antagonistsHUSFELD CRAIG·Filed 2008·Granted Jun 19, 2012·2 cites·16 claims
- 3676US9725448B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Aug 8, 2017·1 cites·8 claims
- 3773US9487514B2Neprilysin inhibitorsFLEURY MELISSA·Filed 2014·Granted Nov 8, 2016·1 cites·20 claims
- 3873US8440702B21,3-oxazolidin -2-one derivatives useful as CETP inhibitorsALI AMJAD·Filed 2011·Granted May 14, 2013·1 cites·21 claims
- 3967US11713315B25 to 7 membered heterocyclic amides as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Aug 1, 2023·0 cites·21 claims
- 4067US9717714B2Spirocyclic CETP inhibitorsMERCK SHARP & DOHME·Filed 2013·Granted Aug 1, 2017·1 cites·3 claims
- 4163US9216971B2Quaternary ammonium compounds useful as muscarinic receptor antagonistsHUSFELD CRAIG·Filed 2014·Granted Dec 22, 2015·0 cites·6 claims
- 4260US8815907B2Quaternary ammonium compounds useful as muscarinic receptor antagonistsHUSFELD CRAIG·Filed 2013·Granted Aug 26, 2014·0 cites·16 claims
- 4360US2014221383A1Cetp inhibitorsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 4460US2018051023A1Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Application pending·0 cites
- 4557US9873696B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·0 cites·4 claims
- 4657US8492407B2Quaternary ammonium compounds useful as muscarinic receptor antagonistsHUSFELD CRAIG·Filed 2012·Granted Jul 23, 2013·0 cites·17 claims
- 4755US12384761B2Imidazolo indazole compounds as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Aug 12, 2025·0 cites·21 claims
- 4855US8450362B2Amidine-containing compounds useful as muscarinic receptor antagonistsJI YUHUA·Filed 2012·Granted May 28, 2013·0 cites·18 claims
- 4951US10428076B2Soluble guanylate cyclase stimulatorsMERCK SHARP & DOHME·Filed 2018·Granted Oct 1, 2019·0 cites·52 claims
- 5051US2016075724A1CETP InhibitorsMERCK SHARP & DOHME·Filed 2015·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →